In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and Human GM-CSF: Assessment of its immunogenicity and toxicity

Iranian Biomedical Journal

Volumn 14, Issue 4, 2010, Pages 136-141

  Oloomi, Mana ^a   Bouzari, Saeid ^a   Shariati, Elaheh ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Cell line; Fusion protein; Toxicity

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN G; SHIGA TOXIN; SHIGA TOXIN A1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA FRAGMENTATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TH1 CELL; TH2 CELL; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; INTERFERON-GAMMA; INTERLEUKIN-4; K562 CELLS; LETHAL DOSE 50; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RABBITS; RECOMBINANT FUSION PROTEINS; SHIGA TOXIN;

MUS;

EID: 79951832871     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kreitman, R.J. (2006) Immunotoxins for targeted cancer therapy. AAPS J. 8: E532-E551.
2. Kreitman, R.J. and Pastan, I. (2006) Immunotoxins in the treatment of hematologic malignancies. Curr. Drug Targets 7: 1301-1311.
3. Hall, P.D., Virella, G., Willoughby, T., Atchley, D.H. Kreitman, R.J. and Frankel, A.E. (2001) Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin. Immunol. 100: 191-197.
4. Westcott, M.M., Abi-Habib, R.J., Cohen, K.A., Willingham, M.C., Liu, S., Bugge, T.H., Leppla, S.H. and Frankel, A.E. (2004) Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factorinduced hepatotoxicity is mediated by Kupffer cells. Mol. Cancer Ther. 3: 1681-1689.
5. Kreitman, R.J. (2004) Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Mol. Cancer Ther. 3: 1691-1692.
6. Hall, P.D., Kreitman, R.J., Willingham, M.C. and Frankel, A.E. (1998) Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colonystimulating factor (GM-CSF) in C57BL/6 mice. Toxicol. Appl. Pharmacol. 150: 91-97.
7. Roudkenari, M.H., Bouzari, S., Oloomi, M., Jafari, A., Shahrokhi, N., and Shokrgozar, M.A. (2005) Expression of a chimeric protein containing the catalytic domain of Shiga-Like Toxin and Human Granulocyte Macrophage Colony-Stimulating Factor (hGM-CSF) in Escherichia coli and its recognition by reciprocal antibodies. Iran. Biomed. J. 9: 143-148.
8. Babich, H. and Borenfreund, E. (1991) Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl. Environ. Microbiol. 57: 2101-2103.
9. Nashar, T.O., Webb, H.M., Eaglestone, S., Williams, N.A. and Hirst, T.R. (1996) potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. USA 93: 226-230.
10. Frankel, A.E., Kreitman, R.J. and Sausville, E.A. (2000) Targeted toxins Clin. Cancer Res. 6: 326-334.
11. Hotchkiss, C.E., Hall, P.D., Cline, J.M., Willingham, M.C., Kreitman, R.J., Gardin, J., Latimer, A., Ramage, J., Feely, T., DeLatte, S., Tagge E.P. and Frankel A.E. (1999) Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colonystimulating factor, in cynomolgus monkeys. Toxicol. Appl. Pharmacol. 158: 152-160.
12. Frankel, A.E., Powell, B.L., Hall, P.D., Douglas Case, L.D. and Kreitman, R.J. (2002) Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. 8: 1004-1013.
13. Kreitman, R.J. (1999) Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11: 570-578.
14. Frankel, A.E., Ramage, J., Latimer, A., Feely, T., Delatte, S., Hall, P., Tagge, E., Kreitman, R. and Willingham, M. (1999) High-level Expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Protein Expr. Purif. 16: 190-201.
15. Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M.P. and Rivoltini, L. (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18: 226-232.